LISTING OF THE CLAIMS:

1.- 20. (Cancelled)

21. (Previously Presented) Radioimmunoconjugate comprising an alpha-emitting radionuclide bound to a monoclonal antibody, wherein said monoclonal antibody is C595.

22. (Previously Presented) Radioimmunoconjugate according to claim 21, wherein said alpha-emitting radionuclide is selected from the group comprising: Tb-149, At-211, Bi-212, Bi-213 and Ac-225.

23. (Previously Presented) Radioimmunoconjugate according to claim 22, wherein said alpha-emitting radionuclide is Bi-213 or Tb-149.

24. (Previously Presented) Radioimmunoconjugate according to claim 22, wherein said alpha-emitting radionuclide is Ac-225.

25. (Previously Presented) Radioimmunoconjugate according to claim 21, wherein said alpha-emitting radionuclide is bound to said monoclonal antibody by a chelating agent.

26. (Previously Presented) Radioimmunoconjugate according to claim 25, wherein said chelating agent is DOTA, cDTPA, DTPA-CHX-A or TETA.

27. (Previously Presented) Radioimmunoconjugate according to claim 21, for use in therapy of breast, prostate, ovarian and/or pancreatic cancer.

28. (Cancelled)

29. (Currently Amended) Method for manufacturing a radioimmunoconjugate, wherein an alpha-emitting radionuclide~~radioisotope~~ is bound to a monoclonal antibody, said monoclonal antibody being C595.

30. (Previously Presented) Radiopharmaceutical for cancer therapy comprising a radioimmunoconjugate of an alpha-emitting radionuclide bound to a monoclonal antibody, wherein said monoclonal antibody is C595.

31. (Previously Presented) Radiopharmaceutical according to claim 30, wherein said alpha-emitting radionuclide is selected from the group comprising: Tb-149, At-211, Bi-212, Bi-213 and Ac-225.

32. (Previously Presented) Radiopharmaceutical according to claim 30, comprising a pharmaceutically acceptable carrier and/or diluent and/or excipient.

33. (Previously Presented) Radiopharmaceutical according to claim 30, wherein said cancer is breast, prostate, ovarian or pancreatic cancer.

34. (Currently Amended) Method of treatment of a mammal affected by a cancer which comprises administering to said mammal a therapeutically effective amount of a radiopharmaceutical comprising ~~a~~ an alpha-emitting radionuclide ~~radioconjugate of an alpha-emitter~~ bound to a monoclonal antibody, said monoclonal antibody being C595.

35. (Previously Presented) Method according to claim 34, wherein said alpha-emitting radionuclide is selected from the group comprising: Tb-149, At-211, Bi-212, Bi-213 and Ac-225.

36. (Previously Presented) Method according to claim 34, wherein said cancer is one of breast, prostate, ovarian and pancreatic cancer.

37. (Previously Presented) Method according to claim 36, wherein said alpha-emitting radionuclide is selected from the group comprising: Tb-149, At-211, Bi-212, Bi-213 and Ac-225.

38. (Previously Presented) Method according to claim 36, wherein said alpha-emitting radionuclide is Bi-213 or Tb-149.

39. (Previously Presented) Method according to claim 34, wherein said radiopharmaceutical is administered as an adjunctive therapeutic treatment.

40. (Previously Presented) Method according to claim 34, wherein said radiopharmaceutical is administered directly after removal of a primary tumour.

41. (Previously Presented) Method according to claim 34, wherein said radiopharmaceutical is administered upon detection of regions of tumour cells at the preangiogenic stage.

42. (Previously Presented) Method according to claim 34, wherein said radiopharmaceutical is administered upon diagnosis of high risk factors in said mammal.

43. (Previously Presented) Method according to claim 34, wherein said radiopharmaceutical is administered upon detection of certain cancer proteins in serum.